Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper
Expert Opin Pharmacother. 2023 Jul 14. doi: 10.1080/14656566.2023.2237410. Online ahead of print.ABSTRACTINTRODUCTION: Major depressive disorder (MDD) is a common, often chronic, and recurring severe mental disorder. Patients with MDD should receive a tailored and integrated approach. Several pharmacological and non-pharmacological treatments are available for patients suffering from major depressive disorders, including several different classes of antidepressant drugs, various psychotherapeutic approaches and psychosocial interventions. The treatment plan for each patient with major depression should be differentiated on...
Source: Expert Opinion on Pharmacotherapy - July 14, 2023 Category: Drugs & Pharmacology Authors: Gaia Sampogna Filippo Caraci Claudia Carmassi Bernardo Dell'osso Silvia Ferrari Giovanni Martinotti Gabriele Sani Gianluca Serafini Maria Salvina Signorelli Andrea Fiorillo Source Type: research
The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States
The objective of this study was to evaluate the pharmacokine tics and bioequivalence of desvenlafaxine succinate in Chinese healthy subjects. A single-dose, open-label, randomized, two-way crossover study with a 7-day washout period was conducted. A total of 88 individuals were incorporated to show bioequivalence of a generic and a reference drug, with 48 ind ividuals in the fasting state and 40 receiving a high-fat diet. Finally, 46 and 38 individuals completed the fasting and the fed study, respectively. The 90% confidence intervals of the adjusted geometric mean ratios for maximum plasma concentration, area under the co...
Source: Clinical Pharmacology in Drug Development - May 27, 2023 Category: Drugs & Pharmacology Authors: Manman Wang,
Yingying Yang,
Wei Hu,
Yue Wang,
Youli Chen,
Xueyuan Zhang Tags: Original Article Source Type: research
Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study
Conclusions: Compared with the SNRI desvenlafaxine, vortioxetine was associated with significantly higher rates of CGI-S remission, better daily and social functioning, and greater treatment satisfaction in patients with MDD and partial response to SSRIs. These findings support the use of vortioxetine before SNRIs in the treatment algorithm in patients with MDD.Trial Registration: ClinicalTrials.gov Identifier: NCT04448431.PMID:37227402 | DOI:10.4088/JCP.23m14780 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - May 25, 2023 Category: Psychiatry Authors: Roger S McIntyre Ioana Florea Mads M øller Pedersen Michael Cronquist Christensen Source Type: research
